Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers developed a nanocomposite microneedle patch containing copper/zinc dual-doped silica nanoparticles, which release substances to promote hair follicle regeneration by targeting various pathophysiological aspects of androgenic alopecia, presenting an effective anti-hair loss treatment strategy.

The researchers developed semi-dissolving microneedle patches using TEMPO-oxidized bacterial cellulose nanofibers, which allow effective transdermal drug delivery by forming micro-channels for large drug quantities, overcoming traditional microneedles' low drug loading.

In this study, researchers observed that atopic dermatitis may alter the appearance of allergic patch test reactions, demonstrating specific patterns like perifollicular erythema and yellowish areas that could aid in interpreting patch tests using dermoscopy, particularly in ambiguous cases.

In this randomized controlled trial, both Botulinum Toxin-A and Triamcinolone Acetonide showed substantial effectiveness in treating patchy Alopecia Areata, but Botulinum Toxin-A avoided complications while Triamcinolone led to skin atrophy in 16.7% of patients.

This study surveyed dermatologists in Greece and Italy and found significant variability and challenges in the diagnosis and treatment of alopecia areata, including limited use of severity scores and diverse treatment approaches, particularly for special site involvement and chronic cases.

In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

This report describes two cases of cutaneous lupus erythematosus mimicking alopecia areata, highlighting the importance of considering CLE in the diagnosis of patchy hair loss to prevent scarring alopecia.

This retrospective cohort study found that individuals with alopecia totalis or universalis have a higher prevalence of systemic autoimmune diseases, particularly endocrine diseases and inflammatory bowel disease, compared to those with patchy alopecia areata.

This study found that patients with patchy alopecia areata had significantly higher serum levels of pro-inflammatory cytokines IL-6, TNF-α, IL-17A, and IL-21 compared to healthy controls, with these levels correlating positively with disease severity, age, and disease duration.

This paper contains author contact information and disclosures without reporting new research findings or results.

This study found that CD2 could be a potential new therapeutic target for treating patchy-type alopecia areata, suggesting the need for further research into its role.

This chapter reviews alopecia areata treatments, highlighting factors like age and disease extent in choosing management strategies, but reports no new clinical findings.

This study aimed to develop a new transdermal patch for treating androgenetic alopecia using finasteride, combined with chemical permeation enhancers to improve drug delivery through the skin, but results of pharmacokinetics and pharmacodynamics evaluations are not reported.

This study found that trichoscopy was 73.77% concordant with histopathology in diagnosing patchy alopecia, highlighting its usefulness as a diagnostic tool for conditions like alopecia areata, lichen planus pigmentosus, and discoid lupus erythematosus.

This study found that a bioorthogonal microneedle patch delivering AAV-aFGF effectively improved hair follicle regeneration and sustained hair growth in murine alopecia models compared to other methods.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

A new microneedle patch effectively and safely treats alopecia areata.

This study identified distinct clinical and dermatoscopic features to differentiate non-scarring patchy alopecia in SLE from alopecia areata, emphasizing the value of serological tests in diagnosis.

In this study, both fractional carbon dioxide laser therapy and cryotherapy were found to be effective and safe for treating patchy alopecia areata, showing similar efficacy in improving hair growth compared to untreated control patches.

This study observed that non-scarring diffuse hair loss was common in systemic lupus erythematosus patients, but did not find a significant relationship with the SLE Disease Activity Index.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This study in Mexican patients with alopecia areata found that body hair involvement was linked to disease progression, while treatment adherence was associated with both remission and progression.

This study found that treatment modalities and patch size influence hair regrowth patterns in alopecia areata patches.

This study observed that patients with new-onset mild alopecia areata had significantly higher levels of oxidative stress markers compared to healthy controls, suggesting their antioxidant defenses may be insufficient to balance the elevated oxidant levels.

In this study, researchers found that patients with new-onset mild alopecia areata had higher levels of oxidative stress markers and reduced antioxidant levels compared to healthy individuals, suggesting that oxidative stress might play a role in the condition.

This article reviews the use of superficial temporal artery island flaps for facial reconstruction and provides a systematic approach for managing composite facial defects, reporting no major complications in 72 patients.

This case study reported that a 29-year-old male patient with alopecia areata patchy experienced hair regrowth and relief from scalp itching and dandruff after using medicinal leech therapy and specific internal medicines for three months.

This study found that topical clobetasol propionate cream provided a modest improvement in hair regrowth for alopecia areata patients, though those with atopy had higher relapse rates after treatment completion.

This study found that dermoscopy showed distinctive patterns for different types of alopecia, supporting its clinical usefulness for diagnosing diseases with small round or oval hairless patches on the scalp.